checkAd

    DGAP-News  603  0 Kommentare Vivoryon Therapeutics N.V.: Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. - Seite 2


     

    ###


    For more information, please contact:
    Vivoryon Therapeutics N.V.
    Dr. Ulrich Dauer, CEO
    Email: contact@vivoryon.com

    Trophic Communications
    Gretchen Schweitzer / Joanne Tudorica
    Tel: +49 172 861 8540 / +49 176 2103 7191
    Email: vivoryon@trophic.eu


    About Vivoryon Therapeutics N.V.
    With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com

    Forward Looking Statements
    Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

    Seite 2 von 3




    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Vivoryon Therapeutics N.V.: Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. - Seite 2 DGAP-News: Vivoryon Therapeutics AG / Key word(s): Corporate Action Vivoryon Therapeutics N.V.: Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. 30.11.2020 / 07:00 The issuer is solely responsible for the content of …